MFWM
RARE icon

Motley Fool Wealth Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Motley Fool Wealth Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.67M Sell
222,981
-74,505
-25% -$1.68M 0.53% 66
2025
Q4 		$6.84M Sell
297,486
-58,054
-16% -$1.91M 0.53% 67
2025
Q3 		$10.7M Buy
355,540
+80,458
+29% +$2.41M 0.73% 50
2025
Q2 		$10M Buy
275,082
+125,486
+84% +$4.52M 0.6% 57
2025
Q1 		$5.42M Sell
149,596
-4,239
-3% -$176K 0.32% 97
2024
Q4 		$6.43M Sell
153,835
-14,180
-8% -$703K 0.33% 91
2024
Q3 		$9.33M Sell
168,015
-2,385
-1% -$121K 0.47% 75
2024
Q2 		$7.01M Buy
170,400
+6,324
+4% +$270K 0.36% 88
2024
Q1 		$7.66M Sell
164,076
-159
-0.1% -$7.5K 0.4% 78
2023
Q4 		$7.86M Sell
164,235
-4,024
-2% -$156K 0.41% 77
2023
Q3 		$6M Buy
168,259
+58,139
+53% +$2.3M 0.35% 86
2023
Q2 		$5.08M Buy
110,120
+4
+0% +$186 0.3% 89
2023
Q1 		$4.42M Buy
110,116
+55,232
+101% +$2.37M 0.28% 87
2022
Q4 		$2.54M Sell
54,884
-1,134
-2% -$44.6K 0.18% 98
2022
Q3 		$2.32M Buy
56,018
+58
+0.1% +$2.98K 0.15% 106
2022
Q2 		$3.34M Sell
55,960
-255
-0.5% -$15.7K 0.21% 96
2022
Q1 		$4.08M Buy
56,215
+71
+0.1% +$4.94K 0.2% 98
2021
Q4 		$4.72M Sell
56,144
-1,948
-3% -$159K 0.21% 93
2021
Q3 		$5.24M Sell
58,092
-1,179
-2% -$107K 0.23% 83
2021
Q2 		$5.65M Sell
59,271
-441
-0.7% -$45.9K 0.24% 89
2021
Q1 		$6.8M Buy
+59,712
New +$8.13M 0.31% 86

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Motley Fool Wealth Management's RARE Position: Q1 2026 in Review

Motley Fool Wealth Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 25% in Q1 2026, selling an estimated $1.68M and leaving 222,981 shares worth $4.67M. The position accounts for 0.53% of the portfolio, ranked #66.

Motley Fool Wealth Management first reported a position in RARE in Q1 2021 and has held it in 21 quarters since. The position peaked at $10.7M in Q3 2025. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Motley Fool Wealth Management held 222,981 shares of Ultragenyx Pharmaceutical worth $4.67M as of Q1 2026.
  • Motley Fool Wealth Management sold 74,505 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.68M.
  • Ultragenyx Pharmaceutical made up 0.53% of Motley Fool Wealth Management's portfolio in Q1 2026, its #66 holding.
  • Motley Fool Wealth Management first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and has held it in 21 quarters since.
  • Motley Fool Wealth Management's Ultragenyx Pharmaceutical position peaked at $10.7M in Q3 2025.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Motley Fool Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.